Anika Therapeutics (NASDAQ:ANIK) Stock Price Expected to Rise, Barrington Research Analyst Says

Anika Therapeutics (NASDAQ:ANIK) had its price objective boosted by stock analysts at Barrington Research from $16.00 to $17.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Barrington Research’s target price would suggest a potential upside of 18.38% from the company’s current price.

A number of other equities research analysts also recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Anika Therapeutics in a report on Monday, December 29th. Wall Street Zen raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Anika Therapeutics Stock Performance

ANIK opened at $14.36 on Friday. The company has a 50-day moving average of $9.96 and a 200-day moving average of $9.57. The company has a market capitalization of $207.07 million, a P/E ratio of -18.89 and a beta of 0.43. Anika Therapeutics has a 1-year low of $7.87 and a 1-year high of $17.74.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.02 by $0.29. The business had revenue of $30.62 million for the quarter, compared to analysts’ expectations of $28.88 million. Anika Therapeutics had a negative net margin of 9.64% and a negative return on equity of 6.21%. As a group, sell-side analysts expect that Anika Therapeutics will post -0.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Anika Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Capital Management Corp VA increased its holdings in shares of Anika Therapeutics by 34.8% in the 3rd quarter. Capital Management Corp VA now owns 551,248 shares of the biotechnology company’s stock worth $5,182,000 after acquiring an additional 142,403 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in Anika Therapeutics by 24.9% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 42,994 shares of the biotechnology company’s stock worth $455,000 after purchasing an additional 8,573 shares during the last quarter. Envestnet Asset Management Inc. grew its position in Anika Therapeutics by 26.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 121,387 shares of the biotechnology company’s stock worth $1,284,000 after purchasing an additional 25,753 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Anika Therapeutics by 6.7% in the second quarter. Acadian Asset Management LLC now owns 575,644 shares of the biotechnology company’s stock valued at $6,084,000 after purchasing an additional 36,030 shares during the period. Finally, State of Wisconsin Investment Board raised its holdings in shares of Anika Therapeutics by 5.5% during the fourth quarter. State of Wisconsin Investment Board now owns 49,596 shares of the biotechnology company’s stock valued at $477,000 after buying an additional 2,580 shares during the last quarter. 91.53% of the stock is currently owned by institutional investors.

More Anika Therapeutics News

Here are the key news stories impacting Anika Therapeutics this week:

• Positive Sentiment: Q4 results beat expectations — non‑GAAP EPS $0.31 vs. $0.02 consensus and revenue $30.6M vs. $28.9M consensus; the beat is the primary near‑term catalyst. Zacks: ANIK Q4 Earnings Beat
• Positive Sentiment: Barrington Research raised its price target to $17 and moved to an “Outperform,” signaling analyst confidence and providing upside to the stock. Benzinga: Barrington Research Upgrade
• Positive Sentiment: Company reiterated 2026 revenue guidance (roughly $114.0M–$122.5M reported) and set an adjusted EBITDA target while highlighting commercial‑channel expansion (commercial channel +22% in Q4, +15% full year), supporting a constructive near‑term growth outlook. GlobeNewswire: Q4 & Full‑Year 2025 Results
• Positive Sentiment: Management emphasized operational streamlining and commercial expansion, and generated positive operating cash flow ($11.2M) and free cash flow ($4.4M) for 2025 — items investors often view favorably for mid‑cycle biotech/medical device firms. Seeking Alpha: 2026 Outlook & Commercial Expansion
• Neutral Sentiment: Earnings call transcript and slide materials are available for details on product cadence, margin drivers and timing of regulatory milestones — useful for investors but not an immediate price mover by itself. SA: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Reported short‑interest data in recent feeds appears to be erroneous (shows zero shares / NaN changes); no clear short‑squeeze signal from the published data. MarketBeat: ANIK Data
• Negative Sentiment: Regulatory risk: the FDA sent a response on the Hyalofast® PMA in January and Anika is preparing responses — this implies additional work/possible delays before approval and commercialization. GlobeNewswire: Regulatory Update
• Negative Sentiment: Company still reports negative net margin and negative return on equity; some analysts project a negative full‑year EPS — these fundamentals limit valuation support until profitability trends improve. MarketBeat: Earnings Summary

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.